Definitive Contract 75N93019C00011
Award Date 6/17/19
Potential Completion Date 4/30/23
Potential Value $600K
Federal Agency
Awardee
Ultimate Awardee
Not listed NAICS Category
Federal Contract Vehicle
- Not listed
Set-Aside Type
Total Small Business
Extent Competed
Full and Open Competition after exclusion of sources
Major Defense Program
Not listed Pricing Type
Firm Fixed Price
Place of Performance
Amherst, NY 14228, USA
Solicitation Procedures
Negotiated Proposal / Quote
Number Of Offers Received
9
Legislative Mandate
Not listed National Interest Action
Not listed Research Type
SBIR Program Phase I Action
Primary Consortia Member
Not listed Similar Awards
- This is a $599,806 firm fixed price definitive contract awarded by the Department of Health and Human Services' National Institutes of Health National Institute of Allergy and Infectious Diseases to Pop Biotechnologies Inc., a Buffalo, NY-based small disadvantaged business. The contract is for research and development of "Multivalent QS-18 Protein Nanoparticles for a Broadly Protective Influenza Virus Vaccine" and has a performance period ending on September 29, 2025. The contract...
- This is a $600,000.00 Firm Fixed Price contract awarded by the National Institutes of Health (NIH), part of the Department of Health and Human Services (HHS), to Nanocomposix, Inc., a small business manufacturer of engineered nanoparticles. The objective is to develop an effective human immunodeficiency virus (HIV) vaccine using engineered nanoparticles loaded with messenger RNA (mRNA) targeted to antigen presenting cells. This contract is part of the Small Business Innovation Research (SBIR)...
- This is a $599,999 Firm Fixed Price contract awarded by the National Institute of Allergy and Infectious Diseases (NIAID), part of the U.S. Department of Health and Human Services, to Parabon NanoLabs, Inc., a small business. The objective of the contract is to develop a DNA-based HIV vaccine that will stimulate production of broadly neutralizing antibodies against the HIV-1 envelope protein trimer antigen. This is a Phase I Small Business Innovation Research (SBIR) contract under the...
- This is a $599,914 firm-fixed-price contract awarded by the National Institute of Allergy and Infectious Diseases (NIAID), part of the U.S. Department of Health and Human Services, to Antagen Biosciences Inc. (doing business as Antagen Pharmaceuticals), a small disadvantaged and minority-owned biotechnology company. The objective of this SBIR Phase I research contract is to develop a nanoparticle-based vaccine delivery platform to induce broadly neutralizing antibodies against HIV. The work will...
- This $299,040 firm-fixed-price Small Business Innovation Research (SBIR) Phase I contract was awarded by the National Institute of Allergy and Infectious Diseases (NIAID), part of the U.S. Department of Health and Human Services, to Nanocomposix, Inc., a small business manufacturer of engineered nanoparticles. The objective is to design and synthesize a new PLGA-based nanoparticle with an optimal protein-adjuvant formulation that combines targeting and controlled delivery for immunization...
- This is a $300,000 firm fixed price definitive contract awarded by the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health, to Neovaxsyn Inc., a minority-owned small disadvantaged business. The contract is for research and development to utilize nanoparticles to deliver MPER-based immunogens and elicit broadly neutralizing antibodies against the HIV-1 virus in order to develop a protective vaccine. This contract was awarded under the Small...
- This federal contract award, with a total ceiling value of $2,250,744.00, was issued by the National Institute of Allergy and Infectious Diseases (NIAID) to the International AIDS Vaccine Initiative (IAVI), a global non-profit organization focused on HIV vaccine development. The purpose of the contract is to develop an optimized Phase 1 current Good Manufacturing Practice (cGMP) manufacturing process for lipid nanoparticle (LNP) fabrication that enables covalent coupling of an HIV-1 envelope...
- This is a Cost Plus Fixed Fee contract awarded by the Department of Health and Human Services (HHS) National Institutes of Health (NIH) National Institute of Allergy and Infectious Diseases to Profectus Biosciences, Inc., a small business. The contract, with a potential value of $3,383,522.51, is for research and development in the biomedical field, specifically focused on applied research and exploratory development of vaccine technologies. The contract does not have a set-aside designation....
- This definitive contract from the Department of Health and Human Services' National Institutes of Health and National Institute of Allergy and Infectious Diseases, valued at $299,999, was awarded to Neovaxsyn Inc. to develop a protective HIV vaccine utilizing gold nanoparticles to elicit broadly neutralizing antibodies against the fusion peptide of HIV-1 GP41. The contract was awarded under the Small Business Innovation Research Program Phase I solicitation, which sought proposals for research...
- This is a federal contract award from the Department of Health and Human Services (HHS) National Institutes of Health (NIH) National Institute of Allergy and Infectious Diseases (NIAID) to International AIDS Vaccine Initiative Inc. (IAVI), a non-profit organization. The $713,906.00 award supports the development of nanoparticle-based delivery systems for human immunodeficiency virus type 1 (HIV-1) biomolecules. The contract has a performance period ending on December 15, 2021 and utilizes a Cost...